Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 19/20 | 0.69 |
| ▸ | KDM1B | Q8NB78 | 5/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.69 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15011508 | 1.00 | KDM1A (0.69) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| SCHEMBL28005458 | 1.00 | KDM1A (0.69) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| SCHEMBL15011361 | 1.00 | KDM1A (0.69) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| SCHEMBL29575947 | 1.00 | KDM1A (0.69) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| SCHEMBL3609223 | 1.00 | KDM1A (0.69) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| SCHEMBL15286633 | 1.00 | KDM1A (0.69) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| SCHEMBL2612405 | 1.00 | KDM1A (0.69) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| SCHEMBL247873 | 1.00 | KDM1A (0.69) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL15282062 | 0.98 | KDM1A (0.67) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL15058586 | 0.98 | KDM1A (0.67) | KDM1AKDM1BKCNH2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 323 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115927239-B | Recombinant aminotransferase, enzyme preparation and use thereof | 重庆普佑生物医药有限公司 | 2025-01-17 | — | — | CN | claimed |
| CN-116283821-B | Phencyclized propylamine compound, preparation method and application | 郑州大学 | 2024-01-26 | — | — | CN | claimed |
| CN-117126059-A | Preparation method of ticagrelor intermediate (1R, 2S) -2- (3, 4-difluorophenyl) cyclopropylamine | 江苏阿尔法药业股份有限公司 | 2023-11-28 | — | — | CN | claimed |
| CN-116283821-A | Phencyclized propylamine compound, preparation method and application | 郑州大学 | 2023-06-23 | — | — | CN | claimed |
| CN-111978327-B | Preparation method of ticagrelor | 南京一心和医药科技有限公司 | 2022-06-10 | — | — | CN | claimed |
| CN-112574124-B | Ticagrelor derivative and preparation method and application thereof | 浙江乐普药业股份有限公司 | 2022-04-26 | — | — | CN | claimed |
| CN-112574124-A | Ticagrelor derivative and preparation method and application thereof | 浙江乐普药业股份有限公司 | 2021-03-30 | — | — | CN | claimed |
| CN-110157766-B | Preparation method of (1R,2S) -2- (3, 4-difluorophenyl) cyclopropylamine | 浙江科技学院 | 2021-03-26 | — | — | CN | claimed |
| CN-112394109-A | Method for detecting impurities in ticagrelor | 武汉武药科技有限公司 | 2021-02-23 | — | — | CN | claimed |
| CN-111978327-A | Preparation method of ticagrelor | 南京一心和医药科技有限公司 | 2020-11-24 | — | — | CN | claimed |
| US-9056838-B2 | Intermediates and processes for preparing Ticagrelor | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2015-06-16 | — | — | US | claimed |
| US-20140350301-A1 | NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR | ACTAVIS GROUP PTC EHF (IS) | 2014-11-27 | — | — | US | claimed |
| US-20140323727-A1 | NOVEL PROCESS FOR PREPARING PHENYLCYCLOPROPYLAMINE DERIVATIVES USING NOVEL INTERMEDIATES | ACTAVIS GROUP PTC EHF (IS) | 2014-10-30 | — | — | US | claimed |
| US-20130165696-A1 | NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR | ACTAVIS GROUP PTC EHF (IS) | 2013-06-27 | — | — | US | claimed |
| US-20130150577-A1 | NOVEL PROCESS FOR PREPARING PHENYLCYCLOPROPYLAMINE DERIVATIVES USING NOVEL INTERMEDIATES | ACTAVIS GROUP PTC EHF (IS) | 2013-06-13 | — | — | US | claimed |
| US-20120130097-A1 | PROCESS FOR THE PREPARATION OF CYCLOPROPYL CARBOXYLIC ACID ESTERS AND DERIVATIVES | ASTRAZENECA AB (SE) | 2012-05-24 | — | — | US | claimed |
| US-20110190520-A1 | Process for the preparation of cyclopropyl carboxylic acid esters and derivatives | ASTRAZENECA AB (SE) | 2011-08-04 | — | — | US | claimed |
| EP-1760066-A2 | Processes for the preparation of cyclopropyl carboxylic acid derivatives and intermediates provided by these processes | AstraZeneca AB (SE) | 2007-03-07 | — | — | EP | claimed |
| US-20060258879-A1 | Process for the preparation of cyclopropyl carboxylic acid esters and derivatives | ASTRAZENECA AB (SE) | 2006-11-16 | — | — | US | claimed |
| US-20030120105-A1 | Process for the preparation of cyclopropyl carboxylic acid esters and derivatives | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258879-A1 | Process for the preparation of cyclopropyl carboxylic acid esters and derivatives | MCCC2, DHPS, CYP3A4 | KDM1A 2952/4885KDM1B 2629/4885KCNH2 3862/4885 |
| US-20030120105-A1 | Process for the preparation of cyclopropyl carboxylic acid esters and derivatives | MCCC2, DHPS, CYP3A4 | KDM1A 2952/4885KDM1B 2629/4885KCNH2 3862/4885 |
| US-20140350301-A1 | NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR | THPO, P2RY4, TBXA2R | KDM1A 3290/4885KDM1B 3834/4885KCNH2 2235/4885 |
| US-20140323727-A1 | NOVEL PROCESS FOR PREPARING PHENYLCYCLOPROPYLAMINE DERIVATIVES USING NOVEL INTERMEDIATES | THPO, P2RY4, TPMT | KDM1A 2919/4885KDM1B 3610/4885KCNH2 1993/4885 |
| US-20110190520-A1 | Process for the preparation of cyclopropyl carboxylic acid esters and derivatives | MCCC2, DHPS, CYP3A4 | KDM1A 2952/4885KDM1B 2629/4885KCNH2 3862/4885 |
| US-20130150577-A1 | NOVEL PROCESS FOR PREPARING PHENYLCYCLOPROPYLAMINE DERIVATIVES USING NOVEL INTERMEDIATES | THPO, P2RY4, TPMT | KDM1A 2919/4885KDM1B 3610/4885KCNH2 1993/4885 |
| US-20130165696-A1 | NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR | THPO, P2RY4, TBXA2R | KDM1A 3290/4885KDM1B 3834/4885KCNH2 2235/4885 |
| US-20120130097-A1 | PROCESS FOR THE PREPARATION OF CYCLOPROPYL CARBOXYLIC ACID ESTERS AND DERIVATIVES | MCCC2, DHPS, CYP3A4 | KDM1A 2952/4885KDM1B 2629/4885KCNH2 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.